NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
FREMONT, Calif., May 03, 2018 -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release first quarter 2018 financial and operating results on Wednesday, May 9, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on May 9, 2018 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and corporate developments.
For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 877-591-4959. For international participants outside the U.S./Canada, the dial-in number is 719-325-2329. For all callers, refer to Conference ID 8804469. To access the live webcast, go to http://asteriasbiotherapeutics.com/inv_events_presentations.php.
A replay of the conference call will be available for one month beginning about two hours after the conclusion of the live call, by calling toll-free (from U.S./Canada) 888-203-1112 ; international callers dial 719-457-0820. Use the Conference ID 8804469. Additionally, the archived webcast will be available at http://asteriasbiotherapeutics.com/inv_events_presentations.php.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) is an autologous cancer immunotherapy with promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML). AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic cancer immunotherapy. The company's research partner, Cancer Research UK, plans to begin a first-in-human (FIH) clinical trial of AST-VAC2 in non-small cell lung cancer. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.
Contacts:
Investor Relations
(510) 456-3892
[email protected]
or
EVC Group, Inc.
Michael Polyviou/Greg Gin
(732) 232-6914
[email protected]
